Comparing the current results to its competitors, Trevi Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.58 %, recorded in the same quarter.
Trevi Therapeutics Inc , slower than the average decrease reported by the company's competitors of -4.68 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -4.68 %
Trevi Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive and rapidly evolving biopharmaceutical industry, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology firms. If successfully developed and commercialized, Haduvio would compete with existing and future therapies for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung diseases (ILD), and refractory chronic cough (RCC). Boehringer Ingelheim previously developed BI 1839100, a TRPA1 antagonist for IPF-related chronic cough and progressive pulmonary fibrosis, but terminated its development in September 2025. Haduvio may also compete with other RCC product candidates, including camlipixant, a P2X3 antagonist developed by GSK plc. Gefapixant, another P2X3 antagonist developed by Merck & Co., Inc., is approved for refractory or unexplained chronic cough in several countries; however, Merck withdrew its FDA application and does not plan to refile.
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Sources:
Trevi Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Trevi Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
